Company Overview and News
Stop missing out on important events!
December has seen the culmination of at least 2 distinct catalysts propel several leading marijuana stocks much higher before the end of the year. (48-1)
LOS ANGELES, CA / ACCESSWIRE / November 28, 2017 / CV Sciences, Inc., (OTCQB: CVSI), preeminent supplier and manufacturer of hemp-derived phytocannabinoids, including CBD oil and developer of specialty pharmaceutical therapeutics, announced today that it will be presenting at the 10th annual LD Micro Main Event on Wednesday, December 6th at 10:30 AM PST / 1:30 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, California. (3-0)
The following slide deck was published by CV Sciences, Inc. in conjunction with their 2017 Q3 earnings call. (3-1)
Greetings and welcome to CV Sciences’ 2017 Third Quarter Conference Call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] Remind you that this conference is being recorded. (9-0)
DENVER, CO--(Marketwired - Oct 19, 2017) - Ubiquitech Software Corp. (OTC PINK: UBQU), through its operating subsidiary HempLifeToday.com, is proud to announce that Forbes Magazine has listed HempLife Today™ among the top five Hemp CBD Companies in gross annual product sales, and that sales of CBD products could hit one billion per year within the next three years. This article was published on August 23rd, 2017; however, the Company chose to wait until 3rd quarter financials were published before bringing this positive article to greater attention. (22-2)
SANTA MONICA, CA / ACCESSWIRE / October 17, 2017 / According to the Centers for Disease Control and Prevention, tobacco use causes almost six million deaths annually, with that number expected to climb to eight million by 2030 based on current trends. In the U.S. alone, about one in five deaths, or approximately 1,300 deaths every day, are the result of cigarette smoking, making it a leading cause of preventable death. (3-1)
NEW YORK, NY / ACCESSWIRE / September 28, 2017 / CV Sciences, Inc. (OTCQB: CVSI) (the ''Company,'' ''CV Sciences,'' ''our," or ''we''), market-leading supplier and manufacturer of hemp-derived cannabidiol (CBD) products and developer of specialty pharmaceutical therapeutics, will be presenting at this year's MicroCap Conference on October 5th in New York City. (3-0)
According to a recent report by New Frontier Data, the Viridian Cannabis Stock Index gained 236.1% in 2016 and outperforming such mainstream indexes as the Russell 2000 (up 19.5%), the Dow Jones Industrial Average (up 13.4%), the S&P 500 (up 9.5%), and the Nasdaq composite (up 7.5%). New Frontier Data also reported that legal cannabis sales in California alone are projected to reach $2.8 billion in 2017 and $6. (35-0)
It is no secret that the legal marijuana market is exploding in North America. Analysts have predicted the cannabis market in the United States could reach $24.1 billion by 2025, and recent polls indicate 61 percent of Americans now believe marijuana use should be federally legalized. Measures are currently being taken in Canada to legalize recreational marijuana by 2018. On a global scale, the worldwide cannabis market has been projected to reach up to $55. (0-1)
LAS VEGAS, NV--(Marketwired - August 15, 2017) - CV Sciences, Inc. (OTCQB: CVSI) (the "Company," "CV Sciences," "our" or "we") highlighted a recent study conducted at Federal University of Prana and Santa Catarina in Brazil which reports that preclinical and clinical studies suggested that cannabidiol (CBD) may help prevent drug addiction relapse. The research cites the effects of CBD drugs on the aversive and rewarding drug-associated memory extinction and reconsolidation, inhibiting the CB1 receptor to suppress reinstatement of drug rewarding memories.
Company to Exhibit and Present amongst Fellow Hemp Industry Leaders, Furthering its Dedication to Advancing Hemp Research, Education and Quality Consumer Products
LAS VEGAS, NV--(Marketwired - August 01, 2017) - CV Sciences, Inc., (OTCQB: CVSI) (the "Company," "CV Sciences," "our" or "we"), cited a recent study conducted by researchers at the University of Louisville School of Medicine suggesting a scientific basis for the potential of cannabidiol (CBD) to have therapeutic value in two neurodegenerative diseases, Alzheimer's and Parkinson's.
Company Enters its Second Year Sponsoring Continuing Education for University Students, Alumni, and Local Practitioners Interested in Learning More about Cannabis-Related Research and Methodologies
NEW YORK, July 24, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of CV Sciences, Inc. (OTC: CVSI).
Company Gaining Traction with Drug Candidate CVSI-007 to Become the Only FDA Approved Treatment for Smokeless Tobacco Addiction
CVSI : CV Sciences Stock Analysis and Research Report
CV Sciences was incorporated under the name Foreclosure Solutions, Inc. in the State of Texas on December 9, 2010. On July 25, 2013, the Company’s predecessor, CannaVest Corp., a Texas corporation (“CannaVest Texas”), merged with the Company, a wholly-owned Delaware subsidiary of CannaVest Texas, to effectuate a change in the Company’s state of incorporation from Texas to Delaware. On January 4, 2016, the Company filed a Certificate of Amendment of Certificate of Incorporation with the Secretary of State of the State of Delaware, reflecting its corporate name change to “CV Sciences, Inc.”, effective on January 5, 2016. In addition, on January 4, 2016, the Company amended its Bylaws to reflect its corporate name change to “CV Sciences, Inc.” The Company previously operated under the corporate name of CannaVest Corp. On June 8, 2016, the Company changed its trading symbol from CANV to CVSI, and continues to be traded on the OTC: QB.
The change in corporate name was undertaken in conn...